
Pimicotinib
CAS No. 2253123-16-7
Pimicotinib( —— )
Catalog No. M37228 CAS No. 2253123-16-7
Pimicotinib (ABSK021) is a potent CSF1R inhibitor with antitumor activity and can be used to study advanced solid tumors.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 90 | Get Quote |
![]() ![]() |
5MG | 136 | Get Quote |
![]() ![]() |
10MG | 208 | Get Quote |
![]() ![]() |
25MG | 365 | Get Quote |
![]() ![]() |
50MG | 605 | Get Quote |
![]() ![]() |
100MG | 945 | Get Quote |
![]() ![]() |
500MG | 1890 | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NamePimicotinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionPimicotinib (ABSK021) is a potent CSF1R inhibitor with antitumor activity and can be used to study advanced solid tumors.
-
DescriptionPimicotinib is a CSF1R inhibitor with antitumor activity.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayTyrosine Kinase
-
TargetCSF1R
-
Recptorc-Fms
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2253123-16-7
-
Formula Weight420.46
-
Molecular FormulaC22H24N6O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (237.83 mM; Ultrasonic )
-
SMILESO=C(NC=1N=C(C(OC2=CC=NC(=C2)C=3C=NN(C3)C)=CC1)C)N4C(=O)C(C)(C)CC4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zhao BW, et al. N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method and application. World Intellectual Property Organization, WO2018214867 A1. 2018-11-29.
molnova catalog



related products
-
Gimsilumab
Gimsilumab (MORAb-022) is a humanized monoclonal antibody targeting granulocyte macrophage colony-stimulating factor for the study of COVID-19-induced inflammation and hypoxemia.
-
Vimseltinib
DCC-3014 is a c-FMS (CSF-IR) and c-Kit dual inhibitor (IC50s: <0.01 μM and 0.1-1 μM) extracted from the patent WO2014145025A2 (Example 10).
-
Mavrilimumab
Mavrilimumab (CAM 3001) is a monoclonal antibody with antiviral activity that targets the α subunit of the granulocytic-macrophage colony-stimulating factor (GM-CSF) receptor, inhibiting downstream intracellular GM-CSF signaling.